Dendritic Cells With Transduced Survivin Gene Induce Specific Cytotoxic T Lymphocytes in Human Urologic Cancer Cell Lines

Urology

Volumn 74, Issue 1, 2009, Pages 222-228

  Kikkawa, Kazuro ^a   Fujii, Reona ^a   Kuramoto, Tomomi ^a   Mori, Takashi ^a   Inagaki, Takeshi ^a   Kohjimoto, Yasuo ^a   Iwahashi, Makoto ^a   Yamaue, Hiroki ^a   Hara, Isao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OKT 8; SURVIVIN;

APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DONOR; GENE; GENETIC TRANSDUCTION; HAPLOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ADENOVIRIDAE; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; UROLOGIC NEOPLASMS;

EID: 67649238728     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.12.045     Document Type: Article

References (18)

1. Zaffaroni N., Pennati M., and Daidone M.G. Survivin as a target for new anticancer interventions. J Cell Med 9 (2005) 360-372
2. Schmidt S.M., Schag K., Müllar M.R., et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102 (2003) 571-576
3. Hart D.N.J. Dendritic cells: unique leukocyte populations which control the primary immuno response. Blood 90 (1997) 3245-3287
4. Nakamura M., Iwahashi M., Nakamori M., et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res 8 (2002) 2742-2749
5. Moussa O., Abol-Enein A., Bissada N.K., et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 175 (2006) 2312-2316
6. Parker A.S., Kosari F., Lohse C.M., et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 107 (2006) 37-45
7. Shariat S.F., Lotan Y., Saboorian H., et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 100 (2004) 751-757
8. Hirohashi Y., Torigoe T., Maeda A., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 (2002) 1731-1739
9. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
10. Giodini A., Kallio M.J., Wall N.R., et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 62 (2002) 2462-2467
11. Rödel F., Hoffmann J., Distel L., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65 (2005) 4881-4887
12. Zhang M., Latham D.E., Delaney M.A., et al. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24 (2005) 2474-2482
13. Kawakami Y., Eliyahu S., Delgado C.H., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91 (1994) 6458-6462
14. Höltl L., Rieser C., Papesh C., et al. Cellular and humoral immuno responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161 (1999) 777-782
15. Burch P.A., Breen J.K., Buckner J.C., et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6 (2000) 2175-2182
16. Nakamura M., Iwahashi M., Nakamori M., et al. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology 68 (2005) 163-170
17. + T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 58 (1998) 5305-5309
18. Nikitina E.Y., Clark J.I., van Beynen J., et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 7 (2001) 127-135